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Ischemic stroke is responsible for many deaths and long-term disability world wide. Devel-
opment of effective therapy has been the target of intense research. Accumulating pre-
clinical literature has shown that substantial functional improvement after stroke can be
achieved using subacutely administered cell-based and pharmacological therapies. This
review will discuss some of the latest findings on bone marrow-derived mesenchymal
stem cells (BMSCs), human umbilical cord blood cells, and off-label use of some phar-
macological agents, to promote recovery processes in the sub-acute and chronic phases
following stroke. This review paper also focuses on molecular mechanisms underlying
the cell-based and pharmacological restorative processes, which enhance angiogenesis,
arteriogenesis, neurogenesis, and white matter remodeling following cerebral ischemia as
well as an analysis of the interaction/coupling among these restorative events. In addition,
the role of microRNAs mediating the intercellular communication between exogenously
administered cells and parenchymal cells, and their effects on the regulation of angiogen-
esis and neuronal progenitor cell proliferation and differentiation, and brain plasticity after
stroke are described.
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INTRODUCTION
Stroke is one of the leading causes of mortality, long-term disabil-
ity, and morbidity. Current stroke treatments have mostly targeted
early neuroprotection,utilizing therapeutic agents designed to pre-
vent or reduce cell damage from ischemia. These agents have
provided promising results in animal stroke models. However,
except for thrombolysis with tissue plasminogen activator (tPA),
to-date, all Phase III clinical trials utilizing them have failed to pro-
vide therapeutic benefit. For now, tPA is the only FDA approved
pharmacological therapy for acute ischemic stroke. Based on the
European Cooperative Acute Stroke Study (ECASS III) (Cronin,
2010; Carpenter et al., 2011), tPA was therefore approved for
thrombolytic therapy of acute ischemic stroke for selected patients
when therapy starts within 4.5 h of stroke onset. However, treat-
ment with tPA is limited by this narrow time window, as well as
by an increased risk for intracranial hemorrhage. Consequently,
only 4–7% of patients in US suffering a stroke receive thrombol-
ysis with tPA (Katzan et al., 2004; Schwammenthal et al., 2006;
Weimar et al., 2006). After decades of research focused on acute
neuroprotection and the failure of clinical trials to overcome this
barrier, the National Institutes of Neurological Disease and Stroke
(NINDS) Stroke Progress Review Group in 2006 and in 2011 iden-
tified delayed neurorestoration after stroke as a major priority for
stroke research (Grotta et al., 2008; NINDS, 2012).
Cell-based and pharmacological restorative therapies are
promising approaches for the treatment of stroke (Modo et al.,
2002a,b; Savitz et al., 2003; Watson et al., 2003; Willing et al., 2003).
Cell-based therapy, e.g., bone marrow stromal cells (BMSC) or
human umbilical cord blood cells (HUCBCs), when administered
intravenously after stroke improves neuroplasticity and neurolog-
ical outcome through the up-regulation of restorative processes
such as: neurogenesis, angiogenesis, and oligodendrogenesis in the
post-ischemic brain (Chen et al., 2001a). Among pharmacological
agents, which promote neurological recovery when administered
subacutely, Niaspan, a slow-releasing vitamin B3 drug has shown
promise as a neurorestorative agent (Chen et al., 2007). In addi-
tion, Niaspan extends the therapeutic window for tPA therapy
(Chen et al., 2001a; Shehadah et al., 2011). Recently, microRNAs
(miRNAs), each of which may regulate the translation of hundreds
of genes and thereby act as molecular master switches, have been
shown to mediate BMSC cell therapy for stroke (Juranek et al.,
2013) and control neuronal progenitor cell proliferation and dif-
ferentiation, and will therefore be discussed here (Lim et al., 2010;
Wang et al., 2013). This review paper will also focus on molecu-
lar mechanisms promoting neurorestorative effects (angiogenesis,
neurogenesis, and oligodendrogenesis) after cerebral ischemia,
which underlie the restorative effects of cellular and experimental
pharmacological approaches for the treatment of stroke.
BIOLOGICAL BASES FOR NEURORESTORATIVE THERAPY
POST-ISCHEMIA
Neurorestoration post-stroke is achieved by enhancing neuro-
genesis, angiogenesis, and oligodendrogenesis, which in concert
promote neurological recovery (Chen et al., 2003b, 2006, 2010;
Chopp et al., 2009; Hermann and Chopp, 2012). Neurogenesis,
the generation of new parenchymal cells from neural stem and
progenitor cells, stimulates plasticity, oligodendrogenesis, restores
neuronal signal transduction, and promotes myelination (Skihar
et al., 2009), Vascular remodeling (angiogenesis and arteriogene-
sis) increases cerebral blood flow (CBF) perfusion and mediates
the generation of important restorative trophic factors and pro-
teases and thereby helps to establish a hospitable environment for
neurite outgrowth, remyelination, and in general for the resident
cells (Chen et al., 2009).
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VASCULAR REMODELING (ANGIOGENESIS AND ARTERIOGENESIS)
Recent findings concerning the pathophysiological events follow-
ing acute ischemic stroke suggest that angiogenesis plays a critical
role in improving long-term recovery of patients (Arenillas et al.,
2007; Navarro-Sobrino et al., 2011). Typically, elderly patients tend
to have lower levels of new vessel formation following stroke,
which may be associated with lower rates of functional recov-
ery (Allen, 1984; Granger et al., 1992). Maintenance of neural
function is critically dependent upon regulation of CBF (Pratt
et al., 2004). Angiogenesis and arteriogenesis reestablish functional
microvasculature in the ischemic border zone (IBZ), creating a
microenvironment hospitable for neuronal plasticity, which can
lead to functional recovery (Plate, 1999; Chen et al., 2003b; Ren-
ner et al., 2003). After stroke, patients who have a higher cerebral
blood vessel density do better and survive longer than patients
having lower vascular density (Krupinski et al., 1994; Wei et al.,
2001). Clinical improvement shortly after stroke also correlates
with the presence of arteriolar collaterals (arteriogenesis). Stroke
mortality increases in the absence of significant collateralization
(Christoforidis et al., 2005). It is therefore reasonable that stimulat-
ing angiogenesis and arteriogenesis may be an effective treatment
strategy for stroke patients.
Angiogenesis leads to mature and functional blood vessels,
which is a therapeutic goal. Angiogenesis refers to the biological
process resulting in the growth of new blood vessels, branching off
from pre-existing vessels. Hypoxia and tissue ischemia are the main
physiological stimuli for angiogenesis (Dor and Keshet, 1997).
Endothelial cell proliferation,migration, and sprouting of new ves-
sels from existing vessels toward the site of ischemic brain injury
are stimulated when angiogenic factors bind to specific recep-
tors located on brain endothelial cells (Greenberg, 1998). This
sprouting of endothelial cells leads to the formation of tube-like
vascular structures. The initial vascular plexus during angiogen-
esis forms mature vessels via branching, pruning, sprouting, as
well as the promotion of differential growth of endothelial cells,
and the recruitment of supporting cells, such as pericytes and
smooth muscle cells (SMCs) (Folkman and D’Amore, 1996; Risau,
1997). Angiogenesis and vascular maturation are regulated by
many factors, such as, Angiopoietin-1 (Ang1)/Tie2 system (Patan,
2004), basic fibroblast growth factor (bFGF), endothelial nitric
oxide synthase (eNOS), platelet-derived growth factor (PDGF),
and vascular endothelial growth factor (VEGF) (Greenberg, 1998;
Lutsenko et al., 2003; Matsui and Tabata, 2012). To determine
the optimal window for the initiation of angiogenic therapies,
a rigorous timetable of angiogenic event steps must be drawn.
Angiogenesis takes place in the penumbra of human ischemic
brain hours after initial onset and continues to be present weeks
after ischemic onset (Krupinski et al., 1994). Nitric oxide (NO) ini-
tiates vasodilation and is considered the first step in angiogenesis
(Carmeliet, 2000). Combining the vasodilation effect of NO with
the increase in VEGF expression, which increases vascular per-
meability allows extravasation of plasma proteins that lay down a
provisional scaffold for the migration of endothelial cells for vas-
cular sprouting. The second step involves the dissociation of SMCs
and loosening the extracellular matrix, which enwraps the mature
vessel. Angiopoietin-2 (Ang2), an inhibitor of Tie2 signaling,
may be involved in facilitating the detachment of pericytes from
endothelial cells, while the matrix metalloproteinase (MMP) fam-
ily of proteinases degrade matrix molecules and further weakens
vascular integrity (Feng et al., 2009). Once the path of sprouting
has been established, proliferating endothelial cells migrate to dis-
tant sites. During this time, an array of molecular signals, including
VEGF, VEGF receptors, and placental growth factor, work in syn-
chrony to guide this process. Once new blood vessel networks are
formed, Ang1, which activates Tie2 receptors, helps to stabilize
networks initiated by VEGF. The angiogenic process is tightly reg-
ulated by growth factors and the up-regulation of specific growth
factors that dictate event progression (Greenberg, 1998; Lutsenko
et al., 2003).
Arteriogenesis adapts existing systems of vessels into functional
ancillary conduits for blood flow to tissues distal to the site of
occlusion of large, peripheral conduit arteries (Buschmann and
Schaper, 1999; Schaper and Buschmann, 1999). This process shares
characteristics with angiogenesis, though different pathways lead
to arteriogenesis. The main differences between arteriogenesis and
angiogenesis reside in the development of collaterals from exist-
ing arterioles, which are activated by the large pressure differences
between perfusion territories, which produce high intravascu-
lar shear stress (Erdo and Buschmann, 2007). The attraction,
adhesion, and activation of circulating cells such as monocytes,
T-cells, and basophils, are responsible for a large percentage
of the vascular–arteriolar growth and remodeling (Schaper and
Buschmann, 1999). The majority of growth factors and prote-
olytic enzymes are secreted by monocytes, and they allow SMCs to
migrate and divide (Scholz et al., 2001). Arteriogenesis results in
the formation of new arterioles, which are believed to occur when
SMCs coat pre-existing capillaries, which are then transformed
into larger diameter channels (Buschmann and Schaper, 2000; van
Royen et al., 2001). Arteriogenesis is a decisive process of altering
existing vessels into functional collateral conduits to bypass occlu-
sions of large peripheral conduit arteries and restore the supply of
oxygen-enriched blood to tissues (Seetharam et al., 2006).
Angiogenesis and arteriogenesis foster functional restoration
after neurological injury by inducing brain plasticity (Risau, 1997;
Plate, 1999; Cramer and Chopp, 2000; Cairns and Finklestein,
2003; Renner et al., 2003; Landers, 2004). Vascular remodeling
promotes neurorestoration, which is the goal of all neurorestora-
tive therapies (Hurtado et al., 2006). Generating new blood vessels
post-ischemia promotes neurorestorative processes such as neu-
rogenesis and synaptogenesis, which foster improved functional
recovery.
WHITE MATTER AND AXONAL REMODELING AND
OLIGODENDROGENESIS
In humans, after stroke or any acute injury to the central ner-
vous system (CNS), functional recovery is highly limited, leaving
many survivors with life-long neurological deficits. The inability
to completely restore function in these individuals can be partially
attributed to inadequate axonal regeneration and neuroplasticity
(Walmsley and Mir, 2007). Preclinical studies demonstrate that
remodeling of the axons starts 2–3 weeks post-stroke (Liu et al.,
2009, 2010). Successful axonal outgrowth in the adult CNS is
critical to brain repair processes after stroke (Hou et al., 2008). Sur-
viving cortical neurons in the peri-infarct motor cortex experience
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axonal sprouting, which can restore connections in the brain
(Carmichael et al., 2001; Carmichael, 2003; Dancause et al., 2005).
Thus, axonal remodeling in the corticospinal system may con-
tribute to spontaneous functional recovery following stroke (Liu
et al., 2009).
Oligodendrogenesis and remyelination play a crucial role in
behavior and functional restoration post-ischemia. Oligodendro-
cytes (OLs) produce the myelin sheaths, which wrap around axons,
facilitating nerve conduction. Oligodendrocyte progenitor cells
(OPCs) differentiate into mature OLs. OLs are highly vulner-
able to ischemic stress, because white matter has lower blood
flow than gray matter, and deep white matter has little collateral
blood supply (Back et al., 2002). OL damage leads to demyeli-
nation, which contributes to neurological and behavior function
deficits. Mounting evidence suggests that inflammatory response
post-ischemia is especially detrimental to white matter cohesion
through the up-regulation of matrix MMPs (Chen et al., 2011).
MMP-9 and MMP-2 have both been shown to increase white
matter lesions (Chen et al., 2011). In the rodent transient mid-
dle cerebral artery occlusion model (MCAo), the number of OLs
decreased between 24 and 48 h after ischemia and increased 1–
2 weeks after reperfusion in the peri-infarct cortex (Tanaka et al.,
2001). Ischemic damage of OL results in demyelination, contribut-
ing to neurological and behavioral functional deficits. Although
mature OLs are considered post-mitotic and unable to proliferate,
the white matter contains an abundance of OPCs that respond to
ischemic injuries (Gensert and Goldman, 1997; McTigue and Tri-
pathi, 2008). Evidence of oligodendrogenesis post-ischemic stroke
has been demonstrated (Iwai et al., 2010).
NEUROGENESIS AND SYNAPTOGENESIS
Neurogenesis and synaptogenesis contribute to post-stroke func-
tional improvement. Adult mammalian neurogenesis takes place
in the subgranular zone (SGZ) and subventricular zone (SVZ) of
the hippocampus (Shehadah et al., 2010a). Under normal condi-
tions, the neural progenitor cell (NPC) population is maintained
through tightly regulated cell apoptosis and proliferation (She-
hadah et al., 2010b). After ischemic stroke onset in rats, the popu-
lation of NPCs significantly expands in the SVZ, and neuroblasts
are systematically recruited and differentiate into mature neurons,
astrocytes, and OLs in the migratory target of the ischemic penum-
bra region (Parent et al., 2002). Forty-eight hours post-ischemic
stroke, NPC proliferation is up-regulated in the SVZ in the adult
rodents by shortening the cell-cycle length from 19 h in non-stroke
SVZ cells to 15.3 h in stroke SVZ cells (Zhang et al., 2006). The
decrease in the duration of the cell cycle is mainly due to a reduc-
tion in the G1 phase (Zhang et al., 2006). A larger percentage
of progenitor cells from the stroke SVZ re-enter the cell cycle
after mitosis than cells from the non-stroke SVZ (Zhang et al.,
2006). Fourteen days post-ischemia, cell-cycle lengthening results
in daughter cells, which exit the cell cycle and differentiate into
neural cells (Zhang et al., 2008). Above evidence suggests that neu-
rorestoration follows a tightly regulated sequence of events with
the initial step of NPC proliferation followed by differentiation
of these progenitor cells into mature neural cells. Following an
ischemic insult, neurogenesis in the SVZ is enhanced and pre-
cursors migrate to the IBZ and differentiate into region-specific
neural phenotypes (Parent et al., 2002). Cell therapies enhance
this endogenous neurogenesis, migration, and differentiation of
neural cells and promote neurological recovery (Chen et al., 2003a,
2013; Munoz et al., 2005; Bao et al., 2011; Zhang et al., 2012b;
Gutierrez-Fernandez et al., 2013).
Synaptogenesis, the process of formation of new synapses,
can be enhanced by angiogenesis, as there is enhanced oxygen
supply to tissue via blood vessels (Zhang and Chopp, 2009).
Increased expression of Synaptophysin, a pre-synaptic vesicle pro-
tein and an indicator of synaptogenesis (Stroemer et al., 1995;
Ujike et al., 2002), has been observed in cell therapy treatments
(Zhang et al., 2012b; Gutierrez-Fernandez et al., 2013) with a cor-
related improvement in post-stroke functional outcome. From our
work in neurorestorative therapies for stroke, we have found that
all agents and cell types that are effective in promoting recovery of
neurological function evoke common responses in cerebral tissue
(Chen et al., 2001a; Li et al., 2001a, 2002; Zhang et al., 2001, 2002;
Wang et al., 2004).
NEUROVASCULAR NICHE
The neurovascular unit is a conceptual model that describes func-
tional interactions and signaling between neurons, capillaries, and
glia in the brain. Since stroke inflicts both neural and vascular
damage, therapeutic interventions targeting the vascular neural
network warrant investigation as a fundamental component for
post-stroke neurorestoration (Zhang et al., 2012a). Angiogenesis
and neurogenesis in the neurovascular niches of the CNS play key
roles in recovery. Based on in vivo and in vitro murine models
of sublethal hypoxia, it has been suggested that the neurovascu-
lar niches of the CNS, in response to hypoxia, trigger HIF-1α-
mediated responses (Madri, 2009). HIF-1α is modulated in part
by NO, modulates brain-derived neurotrophic factor (BDNF),
VEGF, and stromal cell-derived factor 1 (SDF-1), and induces
their autocrine and paracrine signaling, which in turn mediates
endothelial cell and neural stem cell survival and proliferation
(Madri, 2009). Thus, the optimization of the expression levels of
hypoxia-induced induction of HIF-1α and its downstream sig-
naling components BDNF, C–X–C chemokine receptor type 4
(CXCR4), Neuropilin-1 (Nrp-1), NO, SDF-1, and VEGF may max-
imize recovery (Madri, 2009). In a model of focal cortical stroke,
migration of newly formed neurons from the SVZ to cortex, neu-
rogenesis from a glial fibrillary acidic protein (GFAP)-expressing
progenitor cells in the SVZ, and migration of neuroblasts to a
neurovascular niche in peri-infarct cortex can improve behavioral
recovery post-stroke (Ohab et al., 2006). Behavioral recovery is
thus, attributed to a process linking neurogenesis and angiogene-
sis by growth factors and chemokines and to the trophic action of
SDF-1 and Ang1, which are up-regulated by blood vessels within
the neurovascular niche (Ohab et al., 2006).
NEURORESTORATIVE TREATMENT OF STROKE WITH
CELL-BASED THERAPY
HUMAN UMBILICAL CORD BLOOD CELLS
Human umbilical cord blood cells hold great promise as thera-
peutic agents, since they are easy to isolate without serious ethical
and technical problems. HUCBCs are a rich source of mesenchy-
mal and hematopoietic progenitor cells (HPCs). The number of
Frontiers in Human Neuroscience www.frontiersin.org June 2014 | Volume 8 | Article 382 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chen et al. Neurorestorative therapy for stroke
highly proliferative HPCs in bone marrow is equaled or exceeded
by those found in HUCBC (Almici et al., 1995). HUCBCs induce
strong immunomodulatory properties by the host and yet remain
weakly immunogenic themselves (Vendrame et al., 2006; Nikolic
et al., 2008). As observed in an animal stroke model, HUCBCs
inhibit the pro-inflammatory T helper cell type 1 (Th1) response,
while promoting a strong anti-inflammatory T helper 2 (Th2)
response (Vendrame et al., 2004; Nikolic et al., 2008). Numerous
studies having shown that HUCBC treatment of rodents does not
elicit GVHD (Graft Versus Host Disease), a leading cause of death
in patients that have received stem cell transplants (Li et al., 2001b;
Lu et al., 2002; Henning et al., 2004; Hu et al., 2006). Patients who
receive HUCBC transplants from a relative are significantly at a
lower risk of GVHD, and are less likely to reject the transplant
compared to either bone marrow or peripheral blood stem cells
(Takahashi et al., 2007; Morgado et al., 2008). Factors that may
be beneficial to the host brain in vivo are secreted by HUCB-
derived mononuclear cells as they proliferate and differentiate
(Neuhoff et al., 2007). Umbilical cord blood can provide a signif-
icant number of stem/progenitor cells, for hematopoietic as well
as other tissue-specific lineages, including nervous tissue (Li et al.,
2001b; Kozlowska et al., 2007). HUCBCs, when intravenously (i.v.)
administered, migrate selectively to the ischemic area in the brain,
enhancing functional recovery post-stroke (Chen et al., 2001b; Li
et al., 2001b; Zhang et al., 2011).
The mechanism of transplanted HUCBC-induced functional
benefit after stroke is not clear. The beneficial effects of HUCBC
treatment may be due to multiple causes, such as improved cell sur-
vival, increased angiogenesis, nerve fiber reorganization, reduced
inflammation, and trophic actions, among other restorative events
(Vendrame et al., 2006; Arien-Zakay et al., 2011; Liu et al., 2014).
Anti-inflammatory effects
Beneficial effects include reduction in the extent of ischemic dam-
age, and CD8+ T-cell counts in MCAo rat model (Vendrame
et al., 2006). HUCBC treatment at 48 h post-stroke significantly
decreased infiltration of granulocytes and monocytes and reduced
astrocytic and microglial activation in the parenchyma (Newcomb
et al., 2006). Functional recovery from permanent MCAo was also
seen upon intravenous HUCBC administration in spontaneously
hypertensive rats (Miller et al., 2013). While both human CD34−
and CD34+ cells derived from HUCB were found to be equally
competent in stroke treatment, easy attainability of CD34− cells in
comparison to purified CD34+ cells, makes it a promising source
for cell-based therapies for humans (Miller et al., 2013). HUCBC
administration suppresses pro-inflammatory factor expression,
including cytokines, CD45/CD11b-, CD45/B220-positive (+)
cells, nuclear factor-κB (NF-κB) DNA binding activity (Ven-
drame et al., 2005), tumor necrosis factor-α (TNF-α) (Chen et al.,
2008),and suppression of pro-inflammatory isolectin binding cells
(Leonardo et al., 2010), which may lead to functional and anatom-
ical recovery by attenuating neuroinflammation and inducing
neuroprotection (Vendrame et al., 2005; Leonardo et al., 2010).
Trophic factor effects
The therapeutic benefits of HUCBC treatment likely derive from
enhancement of endogenous brain recovery mechanisms (Chen
et al., 2001b). Only a small percentage of HUCBCs employed to
treat stroke expresses proteins phenotypic of neural-like cells and
functional recovery occurs within days after HUCBC administra-
tion (Chen et al., 2001b). Additionally, the number of HUCBCs
administered intravenously that enter the brain was small, and
the tissue that was replaced would make up no more than a
cubic millimeter. HUCBC treatment of stroke also elevated lev-
els of glial cell-derived neurotrophic factor (GDNF), nerve growth
factor (NGF), and BDNF, thus, trophic factor-mediated mecha-
nisms contribute to improved behavioral outcome, rather than
cell replacement (Yasuhara et al., 2010). HUCBCs contain many
hematopoietic colony-forming cells (CFS) (Nakahata and Ogawa,
1982), as well as produce IL-11 and thrombopoietin (Suen et al.,
1994). CSF-1, a hematopoietic cytokine, is a CNS growth factor
(Berezovskaya et al., 1995). As such, it is likely that HUCBCs act as
sources of trophic factors (Chen et al., 2008). In spinal cord injury
(SCI), treatment with HUCBCs in rats increased serum levels of
GDNF, IL-10, and VEGF, which may contribute to the observed
beneficial effects (Chen et al., 2008). Cytokines and growth fac-
tors in murine NPCs are survival and/or differentiation factors
(Mehler et al., 1993) that may play a critical role in neural tis-
sue proliferation or differentiation (Cairns and Finklestein, 2003).
When HUCBCs are administered intravenously and migrate to the
injured tissue, they may function as a site of trophic factor pro-
duction, which bypasses the blood–brain barrier (BBB). Therefore,
functional benefit of i.v. administration of HUCBC, likely,does not
derive from cellular replacement of tissue but from trophic factor
expression by the injected cells and/or induced by the injected cells
within the parenchymal tissue (Chen et al., 2008; Liu et al., 2014).
Studies also point at OL protection and survival as a means
of HUCBC-induced neuroprotection (Rowe et al., 2010, 2012).
Umbilical cord blood cell-derived CD34+ cells promote angio-
genesis, neurogenesis (Chen et al., 2013), neuronal regeneration
resulting in enhanced neovascularization (Taguchi et al., 2004),
which amplifies the neurorestorative effects and improves func-
tional recovery after stroke. But without reducing infarct volume
and, necessarily, providing neuroprotection (Nystedt et al., 2006).
MULTIPOTENT MESENCHYMAL STEM CELLS
Mesenchymal stem cells (MSCs) can be isolated from bone mar-
row (most common), cord blood cells, placenta, muscle, skin,
and even liposuction fat. In this review, we will focus on MSCs
derived from bone marrow. BMSCs are constituted by a hetero-
geneous collection of mesenchymal stem and progenitor cells.
Human BMSCs (hBMSCs) can transdifferentiate into neural and
mesodermal cell lines (Friedenstein et al., 1968, 1987; Bianco and
Gehron Robey, 2000). In animal models, post-stroke hBMSCs
transplantation improves sensory–motor function (Chen et al.,
2001a; Zhao et al., 2002; Chen and Chopp, 2006; Weng et al.,
2008; Huang et al., 2013b), enhances synaptogenesis (Weng et al.,
2008), stimulates nerve regeneration (Tohill et al., 2004), decreases
tPA-induced brain damage (Liu et al., 2012), and can mediate
immunomodulatory effects and reduce inflammation (Yoo et al.,
2009).
BMSC transplantation induces neurorestorative effects and
ameliorates neurological functional deficits after stroke (Chen
et al., 2001a, 2003a; Shen et al., 2007). We have demonstrated
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that BMSC therapy can reduce neurological functional deficits
when administered intravenously at 1 or 7 days after stroke (Chen
et al., 2001a) and even at 1 month after stroke (Shen et al., 2007).
Transplanted adult BMSCs migrate to damaged tissue in brain
and decrease post-stroke functional deficits (Chen et al., 2001a).
Migration may be aided by the disruption of BBB enabling selective
entry of BMSCs into ischemic brain compared to normal cerebral
tissue. Neurological benefit is derived mainly by triggering the
release of growth and trophic factors, as a very small percentage
of cells migrate, differentiate, and contribute toward neuroprotec-
tion/restoration. BMSCs trigger the release of growth factors in
ischemic tissue that can initiate cell repair mechanisms, enhance
cell proliferation in SVZ, and reduce apoptosis and neuronal
death/damage in ischemic region (Li et al., 2002).
The mechanisms of action of BMSC treatment of stroke signif-
icantly differ from those initially targeted for progenitor and stem
cells. Progenitor and stem cells are placed in the injured brain,
they are designed to replace injured and dead tissue (Riess et al.,
2002). It is likely that BMSCs also contain a stem-like subpopu-
lation of cells that can differentiate into brain cells (Zhang et al.,
2009; Shichinohe et al., 2010; Ding et al., 2011). However, this is a
minor subpopulation of BMSCs where only a minute percentage
assumes a parenchymal cell phenotype, and do not contribute to
functional recovery (Li et al., 2002).
Transplanted BMSCs, by releasing soluble trophic factors and
cytokines, promote endogenous repair of neurologically damaged
tissues (Hardy et al., 2008). We and others have shown that exoge-
nous cells produce various factors, and more importantly, stim-
ulate neuroprotective (Chen et al., 2003a) and neurorestorative
factor production in parenchymal cells. Intravenously adminis-
tered BMSCs used to treat stroke or CNS disease produce trophic
factors and stimulate parenchymal cells to express trophic fac-
tors (Chen et al., 2003b). BMSCs express mRNAs covering a
wide range of angiogenic/arteriogenic cytokines that include Ang1,
basic fibroblast growth factor-2 (FGF2), insulin-like growth fac-
tor (IGF), placental growth factor, and VEGF (Chen et al., 2003b;
Zacharek et al., 2007). hBMSCs that had been cultured with extract
from ischemic rat brain showed increased levels of BDNF, hepa-
tocyte growth factor (HGF), and VEGF (Chen et al., 2002a,b).
Intravenous administration of BMSCs leads to a time dependent
release of neurotrophins and angiogenic growth factors like BDNF,
VEGF, bFGF, NGF, HGF, and GDNF (Chen et al., 2002a,b, 2003b;
Zacharek et al., 2007; Wakabayashi et al., 2010). These cytokines
and growth factors have both autocrine and paracrine activities
(Matsuda-Hashii et al., 2004), which are the molecular signals of
the body uses to regulate differentiation, proliferation, and cell
survival. GDNF promotes neurogenesis, endogenous cell repair
mechanisms, neuroblast proliferation, and migration from the
SVZ and decreases apoptosis (Kobayashi et al., 2006; Yuan et al.,
2013). Intravenously injected BMSCs enter the brain and stimu-
late the local parenchymal cells, mostly astrocytes and endothelial
cells, to produce growth factors promoting angiogenesis and vas-
cular stabilization, which are partially mediated by Ang1/Tie2 and
VEGF/Flk1 (Zacharek et al., 2007). Elevated IGF-1 mRNA expres-
sion was seen in cells subjected to ischemic stress and enhanced
IGF-1 mRNA, IGF-1, and IGF-1R immuno reactive cells seen upon
treatment with BMSCs, indicating that IGF-1-mediated self repair
mechanism may contribute to the gain in neurological function
(Wakabayashi et al., 2010).
BMSCs increase angiogenesis and arteriogenesis (Kinnaird
et al., 2004; Zhu et al., 2011). BMSC conditioned cell culture media
promotes integration and proliferation of endothelial cells and
SMCs in vitro, and when injected directly into the hind limb of
an ischemic mouse, this media enhanced collateral flow recov-
ery and remodeling (Zhu et al., 2011). Treatment with autologous
BMSCs significantly increased arteriogenesis and improved blood
flow in the chronic limb ischemia model (Zhu et al., 2011). BMSCs
selectively migrate to the site of injury, participate in angiogenesis
and arteriogenesis, as well as induce a neovascular response that
results in a significant increase in blood flow to the ischemic area,
aiding the repair of the injured brain (Cui et al., 2009). Trophic and
growth factor production is stimulated from angiogenic and arte-
riogenic vessels by BMSCs, which enhance brain plasticity and
recovery of neurological function after stroke (Kinnaird et al.,
2004). Therefore, it is possible to think of BMSCs as behaving like
small biochemical “factories,” busily producing as well as inducing
many cytokines and trophic factors in vascular and parenchymal
cells that contribute to the improvement of functional outcome
after stroke (Liu et al., 2014). Intracarotid BMSC transplantation
also promotes white matter remodeling in the cortical IBZ and
corpus callosum by increasing axonal sprouting and remyelina-
tion (Shen et al., 2006). Other beneficial effects observed upon
BMSC treatment include enhanced structural neuroplasticity and
increased axonal outgrowth from healthy brain tissue (Andrews
et al., 2008).
miRNA on MSC-induced neurorestorative effects
microRNAs are short sequences of non-coding RNA (ca. 22
nucleotides) found in animals and plants, which regulate gene
expression both transcriptionally and post-transcriptionally. miR-
NAs can regulate many genes, pathways, and biological networks,
either acting alone or with other miRNAs. It appears that miRNAs
act like molecular rheostats, fine-tuning many biological processes
regulating tissue repair like angiogenesis, inflammation, hypoxia–
response, and stem cell biology by affecting gene regulation (Sen,
2011). Therapies aiding in tissue repair based on miRNAs are
beginning to hold promise as we learn how to control and manip-
ulate cell-specific miRNAs (Juranek et al., 2013). However, using
miRNAs as therapeutic targets still hold many challenges, due to
possible delivery and potential off-target effects. Cell-based ther-
apy may be an effective means to manipulate miRNA expression
(Juranek et al., 2013). Cells delivered by intravenous injection
release microvesicles that contain enriched miRNA that can in turn
stimulate endogenous brain cells to express and release miRNA,
ultimately promoting neurorestorative effects after stroke (Juranek
et al., 2013).
BMSCs are abundantly present in our body and they secrete
extracellular vesicles, which depending on parent phenotype, may
carry miRNA, mRNA, proteins, lipids, etc (Katsuda et al., 2013)
and transport miRNAs from cells of origin to target cells (Collino
et al., 2011). miRNAs play a key role in BMSC neuronal differenti-
ation during which miR-34a is downregulated. miR-34a mediates
neuronal precursor motility, that is crucial for homing of stem
cells to target tissue (Chang et al., 2011). In addition, miR-96,
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miR-124, and miR-199a regulate gene expression critical for dif-
ferentiation of BMSCs, and were expressed differentially during
adipogenic, chondrogenic, and osteogenic induction of hBMSCs
(Laine et al., 2012). miRNAs regulate neurogenesis, mediate the
trans-differentiation of MSCs into functional neurons and are
also useful in restoration of lost or damaged neurons in neuro-
logical disorders (Lim et al., 2010). miRNAs, with their varied
biological functions and regulatory capabilities, open new avenues
and strategies for BMSC therapy and manipulation with potential
therapeutic benefits.
Microvesicles provide bidirectional miRNA exchange between
injured cells and BMSCs, which in turn facilitates neuronal differ-
entiation and activation of regenerative pathways in injured cells.
These extracellular vesicles can mediate intracellular communi-
cation and be manipulated to induce therapeutically beneficial
effects. While in resting or active states, BMSCs secrete microvesi-
cles, both microparticles and exosomes that can be manipulated
to deliver miRNAs to enhance recovery of injured tissues (Wang
et al., 2013). A novel treatment strategy for malignant glioma
using miRNAs that are known to have anti-tumor properties (e.g.,
miR-146b), employs exosomes secreted by BMSCs transfected
with miR-146b as a delivery vehicle to decrease tumor volume
(Katakowski et al., 2013). Exposure to ipsilateral ischemic tissue
extracts obtained from MCAo rats elevates miR-133b expression
in BMSCs and in exosomes derived from BMSCs (Juranek et al.,
2013). miR-133b transfer from BMSCs to neurons and astrocytes
results in an increased miR-133b level, and when exposed to post-
MCAo brain extracts for 72h, a significant increase in neurite
branch number and total neurite length is observed. Neurite out-
growth also can be promoted by delivery of miR-133b to neurons
and astrocytes by transfer from BMSCs via exosomes (Juranek
et al., 2013). Manipulation the expression of miR-133b in BMSCs
and thus, in their exosomes, regulates neurological recovery after
stroke (Xin et al., 2013). These data clearly indicate that BMSCs
mediate their functional benefit post-stroke, by the transfer of
exosomes with active miRNAs to parenchymal cells. The miRNAs,
and as shown specifically for the transfer of miR-133b, regulate
their downstream targets, and thereby impact brain plasticity, and
neurovascular remodeling to promote neurological recovery (Xin
et al., 2013).
Therapeutic modulation of individual miRNAs generated by
BMSCs, and either mimicking or antagonizing miRNA actions,
may enhance BMSC therapeutic efficacy. For example, miR-126
is expressed in endothelial cells in blood vessels and capillar-
ies, and mediate angiogenesis (Nikolic et al., 2010). Transplan-
tation of BMSCs over-expressing miR-126, increases the release
of angiogenic factors, improves resistance against hypoxia, and
activates Notch ligand Delta-like-4, thereby enhancing functional
angiogenesis in the ischemic myocardium and improves car-
diac function (Huang et al., 2013a). Increased angiogenesis and
improved cardiac function may be attributed to stimulation of
AKT/ERK-related pathway (Chen and Zhou, 2011). Abnormal
down-regulation of miR 146a has been implicated in mediat-
ing chronic inflammatory responses that interfere with wound
healing in diabetic subjects (Xu et al., 2012). BMSC therapy for
post-myocardial infarction, increases miR-146a expression and
decreases the expression of pro-inflammatory factors. MiRNAs
are also involved in nearly every aspect of the presumed repair
mechanisms of BMSC-based therapies in myocardial infarction,
such as neovascularization and stem cell differentiation (Wen et al.,
2012). Hence, the use of miRNAs as novel regulators and therapeu-
tic modulation of individual cardiovascular miRNAs of BMSCs
have been proposed to improve therapeutic efficiency (Wen et al.,
2012). Treatment of stroke with exosomes derived from BMSCs,
i.e., without the parent BMSC, improves functional outcome, as
well as enhances angiogenesis, neurogenesis, and neurite remodel-
ing. This approach,of using purely exosomes derived from BMSCs,
represents a potentially novel stroke treatment, with possible broad
therapeutic applications (Xin et al., 2013).
STROKE CLINICAL TRIAL FOR CELL-BASED THERAPY
Isolating MSCs from bone marrow for transplantation is consid-
ered safe, having been widely tested in numerous clinical trials with
encouraging results (Bang et al., 2005; Sykova et al., 2006). BMSC
therapies are being evaluated via 79 registered clinical trial sites
located throughout the world (Malgieri et al., 2010). Clinical tri-
als conducted to study intravenous infusion of autologous BMSCs
had promising results, showing that BMSCs appear to be a safe
and are a feasible therapy for improving functional outcome in
stroke patients (Bang et al., 2005; Suarez-Monteagudo et al., 2009;
Lee et al., 2010). Autologous BMSCs were intravenously infused
in a series of patients from South Korea suffering from cerebral
infarcts in the middle cerebral artery (Bang et al., 2005). Stud-
ies, serial evaluations, and comparisons to control group (did not
receive MSCs) for 1 year revealed that the treatment is safe and
may improve functional recovery. A follow up long-term evalua-
tion report recorded higher survival among treated patients than
control group and revealed no significant side effects, indicating
that autologous BMSCs delivered i.v. is safe and may improve func-
tional recovery (Lee et al., 2010). A Phase I/II clinical trial has been
initiated by researchers at University of California San Diego with
other collaborators in which allogenic BMSCs are being evalu-
ated to treat ischemic stroke (NCT01297413). A Phase I/II clinical
trial in Spain revealed feasibility, safety, and improved neurolog-
ical outcome in stroke patients transfused intra-arterially at 5
and 9 days after stroke with autologous bone marrow mononu-
clear cells (Moniche et al., 2012). During the follow up period of
6 months, no adverse effects, deaths, tumor formation, or stroke
recurrence were reported, except for two isolated partial seizures
at 3 months post treatment. From a study of a small group of
ischemic stroke patients with infarcts in the middle cerebral artery
region, it was found that the delivery of umbilical cord MSCs via
intra-arterial catheterization is safe and may contribute to func-
tional improvements (Jiang et al., 2012). There are several other
ongoing studies to test the safety and efficiency of umbilical cord
blood therapy, umbilical cord blood mononuclear cells, to treat
stroke subjects (NCT01884155, NCT01673932).
NIASPAN TREATMENT PROMOTES BRAIN PLASTICITY
AFTER STROKE
There is a growing body of evidence that strengthens the link
between brain high-density lipoprotein (HDL)-C metabolism and
factors involved in synaptic plasticity. Scavenger receptor class B1
(SR-B1) binds HDL and facilitates α-tocopherol and cholesteryl
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esters transfer into cells from circulating HDL. Mice with knocked
out scavenger receptor (SR-B1) exhibited deficient synaptic plas-
ticity, as measured by long-term potentiation of the CA1 hip-
pocampus region, which leads to impaired recognition and spatial
memory (Chang et al., 2009). Furthermore, mice that lacked ATP-
binding cassette transporter A1 (ABCA1) in the CNS exhibit
reduced plasma HDL-C levels and altered synaptic morphology,
including reduced synapse and synaptic vesicle numbers (Karasin-
ska et al., 2009). Niacin is one of the most potent HDL-C promoter
drugs used in the clinic. Niaspan, an extended release formula-
tion of Niacin, may be effective in reducing neurological deficits
post-stroke by promoting axonal remodeling, angiogenesis, and
arteriogenesis (Chen et al., 2007, 2009; Cui et al., 2010; Yan et al.,
2012).
Successful axonal sprouting and remodeling in the penumbra
region is a critical step in nerve regeneration and brain repair.
Niaspan, when administered 24 h after MCAo significantly up-
regulates neuronal synaptic rewiring in the per-infarct region and
restores connections between different cerebral areas after stroke
(Cui et al., 2010; Yan et al., 2012). The increase in axonal den-
sity and synapse formation translates into long-term functional
recovery after experimental stroke (Cui et al., 2010).
Niacin-induced increase in synaptic plasticity and axon growth
may be mediated by the up-regulation in the BDNF–TrkB axis
(Cui et al., 2010). In the mature nervous system, BDNF/TrkB
plays an important role in regulating neuronal migration, dif-
ferentiation, synaptic remodeling, and survival. Niacin treatment
after stroke significantly increases BDNF/TrkB expression both in
the ischemic brain and in primary cortical neuron (PCN) cul-
tures. Furthermore, a TrkB inhibitor significantly decreases HDL
and niacin-induced neurite outgrowth, which indicates that the
BDNF/TrkB axis may mediate, niacin/HDL-induced synaptic plas-
ticity and axon growth (Cui et al., 2010). In addition, the Ang1
molecular pathway also plays a partial role in Niaspan-induced
axonal outgrowth (Yan et al., 2012). Niaspan significantly increases
Ang1 expression. Ang1, in addition to being a promoter of angio-
genesis and vascular maturation, is also a neurotrophic factor and
promotes axonal outgrowth (Yan et al., 2012). In type 1 diabetes
(T1DM) rats subjected to MCAo, Niaspan treatment attenuated
Ang2 and increased Ang1 expression (Yan et al., 2012).
Early stroke recovery is linked to arteriogenesis (Christoforidis
et al., 2005; Liebeskind, 2005). Occlusion of intracerebral arteries
elevates fluid shear stress and thus primes the brain for arteriogen-
esis. Cellular interaction of the endothelial cells in the vascular wall
with cytokines like monocyte chemoattractant proteins-1 (MCP-
1), TNF-α, and cell adhesion molecules facilitates arteriogenesis,
typically triggered by the development of elevated shear stress
in the vessel (Hoefer et al., 2002). TNF-α is a pivotal modula-
tor of arteriogenesis and the TNF-α-converting enzyme (TACE) is
the primary protease responsible for pro-TNF-α activation (Chen
et al., 2009). Treating stroke with Niaspan significantly increases
CBF in the ischemic brain, as measured by magnetic resonance
imaging (MRI), resulting in increased arterial diameter and pro-
liferation of vascular SMC (VSMC). Treatment with Niaspan
increases cultural arterial sprouting and VSMC migration in vitro.
The increase in arterial sprouting and VSMC migration in stroke
after Niaspan treatment is partially attributed to the increased
expression of TACE in the ischemic brain and cerebral arteries
(Chen et al., 2009).
High-density lipoprotein, in addition to promoting arteriogen-
esis, also up-regulates angiogenesis post-ischemic stroke (Chen
et al., 2007). Recent findings in human and in vitro cell cul-
ture show that niacin impedes apolipoprotein A-1 (APO A-1)
hepatic catabolism, thus prolonging HDL half-life (Jin et al.,
1997; Kamanna and Kashyap, 2008). HDL promotes endothelial
progenitor cell incorporation, endothelial cell migration, and re-
endothelialization, all of which are mediated by eNOS and phos-
phoinositide 3-kinase (PI3k)/Akt kinase activation (Shehadah
et al., 2010b). Treatments that combine low doses of Niaspan and
tPA administered 4 h after stroke significantly improved functional
outcome, reduced lesion volume, decreased expression of TLR4
and TNF-α, and decreased apoptosis in MCAo rats (Shehadah
et al., 2011). Combination of Niaspan with Simvastatin helped
improve overall functional outcome significantly and decreased
axonal damage and density (Shehadah et al., 2010a).
CONCLUSION
Primary physiological mediators of neurorecovery post-stroke,
including angiogenesis, arteriogenesis, neurogenesis, and white
matter remodeling, have been described in this review. In addition,
select cell-based therapies (HUCBCs and BMSCs), and an example
of a restorative pharmacological agent, Niaspan, which increases
HDL, which amplifies these restorative processes as restorative
treatments for stroke have been discussed. Elucidating the under-
lying mechanisms of cell-based and pharmacological restorative
therapies is of primary interest and crucial for translation of treat-
ments to clinical use. miRNAs are major molecular regulators and
appear to have pivotal roles in cell-based and possibly pharma-
cological restorative therapies for stroke. Clarification of their
roles in mediating neurorecovery post-stroke, warrant further
investigation.
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